ACET - FDA clears IND application for Adicet Bio's CAR T cell therapy candidate
2024-06-24 09:03:53 ET
Adicet Bio ( NASDAQ: ACET ) shares gained in early trading on Monday after the U.S. drug regulator cleared the company’s Investigational New Drug (IND) application to evaluate its CAR T cell therapy candidate, ADI-270, in relapsed/refractory renal cell carcinoma....
FDA clears IND application for Adicet Bio’s CAR T cell therapy candidate